Rat And Mouse Model Market Size, Growth, Share | Industry Trends 2022-2030

The global Rat And Mouse Model market size is expected to be worth around US$ 6.9 billion by 2030, according to a new report by Vision Research Reports.

The global Rat And Mouse Model market size was valued at US$ 2.9 billion in 2020 and is anticipated to grow at a CAGR of 6.5% during forecast period 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38979

Report Coverage

Report Scope Details
Market Size US$ 6.9 Billion by 2030
Growth Rate CAGR of 6.5% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Type, Technology, Service, Application, End-use
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Charles River Laboratories International, Inc.; The Jackson Laboratory; Laboratory Corporation of America Holdings (Covance); Perkin Elmer (Horizon Discovery Group plc); genOway; Envigo; JANVIER LABS; Taconic Biosciences Inc.; Biomedical Research Models (Biomere); Transpogen Biopharmaceutical, Inc

Growth Factors

The growth of this market is majorly driven by the increasing demand for genetically modified models to help researchers identify and validate therapeutic targets. Additionally, increasing expenditures in R&D activities in the pharmaceutical and biotechnology sector is likely to fuel market growth.

The growth of personalized medicine boosts the demand for humanized rat and mouse models across the globe. Charles River Laboratories offers custom rare disease and microbiome models that support personalized therapy drug trials. The growing need for primary tissue/cells and human-like animal models propel the demand for customized models to assess safety, efficacy, and target validation in cellular therapies.

By Type Analysis

The outbred segment dominated the market for rat and mouse model and accounted for the largest revenue share of 22.6% in 2020. These models accurately represent the genomic structure of humans and hence are employed in research involving human subjects.

Inbred strains accounted for the second-largest revenue share of the market owing to the advantages offered by them in disease research. These models are economical, readily available, homogenous, and are genetically stable.

The knock-in segment is expected to witness the fastest CAGR in the market for rat and mouse model over the forecast period as they can be used to determine the effects of minute changes in the function and structure of proteins.

By Technology Analysis

Based on technology, the CRISPR/Cas9 technology segment dominated the market for rat and mouse model and accounted for the largest revenue share of 22.4% in 2020.

The use of CRISPR knock-in and knock-out rodent models in research involving human diseases has shown promising results. For instance, the application of CRISPR/CAS 9 to edit the β-globin gene has successfully enhanced the level of fetal hemoglobin for the treatment of sickle-cell diseases in mice.

By Service Analysis

Based on the services, the breeding segment dominated the market for rat and mouse model and accounted for the largest revenue share of 31.4% in 2020. This is attributed to the increasing demand for rat and mouse models for the development and drug discovery and subsequent increase in the demand for personalized medicines.

The cryopreservation segment is expected to witness the fastest CAGR throughout the forecast period. Cryopreservation of embryo and sperm from rat and mouse models creates a cost-efficient backup of live animal colonies which do not have many applications in the present scenario but may prove to be extremely useful in the future.

Cryoservices offered by key companies, such as Charles River Laboratories, help in the protection of animal lines in case of natural disaster, a catastrophic accident, microbial contamination, and alteration of gene expression in later generations.

By Application Analysis

The cancer segment dominated the market for rat and mouse model and accounted for the largest revenue share of 17.9% in 2020. Rat and mice models provide various aspects of progression, genesis, and clinical course of human cancers.

With the successful development and implementation of mRNA vaccines for COVID-19, their makers are now exploring ways to use mRNA therapies for other diseases including cancer.

A rise in initiatives to utilize rodent models for cancer drug development is expected to increase the revenue generation in this segment.

By End-use Analysis

The pharmaceutical and biotechnology companies segment held the largest revenue share of 41.9% in 2020. Increasing applications of the rat and mice model in the production of vaccines for infectious diseases are expected to boost the segment further during the forecast period.

The development of mouse models that can generate a human version of ACE2 has increased their adoption rate in the pharmaceutical and biotechnology companies for COVID-19 research.

By Regional Analysis

North America dominated the rat and mouse model market and accounted for the highest revenue share of 49.8% in 2020. This is attributed to the presence of key market players and the growth in pharmaceutical as well as research sectors in this region.

Europe held the second-largest market share owing to the rise in research activities involving the use of rodent models. The researchers have also successfully tested gene therapy which cures alterations of the whole body observed in rat models with Morquio A disease.

Key Players

  • Charles River Laboratories International, Inc.
  • The Jackson Laboratory
  • Laboratory Corporation of America Holdings (Covance)
  • Perkin Elmer (Horizon Discovery Group plc)
  • genOway
  • Envigo
  • JANVIER LABS
  • Taconic Biosciences, Inc.
  • Biomedical Research Models (Biomere)
  • Transpogen Biopharmaceutical, Inc.

Market Segmentation

  • By Type
    • Knockout
    • Knock-in
    • Outbred
    • Inbred
    • Others
  • By Technology
    • Nuclear transferase
    • Microinjection
    • Embryonic stem cells
    • CRISPR/Cas9
    • Others
  • By Service
    • Cryopreservation
    • Breeding
    • Rederivation
    • Genetic testing
    • Quarantine depending
    • Others
  • By Application
    • Cardiovascular diseases
    • Genetic diseases
    • Cancer
    • Infectious diseases
      • COVID-19
      • Others
    • Transplantation
    • Toxicology studies
    • Others
  • By End-use
    • Pharmaceutical companies
    • Academic and research facilities
    • Biotechnology companies
    • Contract research & manufacturing organizations
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
    • Asia Pacific
      • China
      • Japan
      • India
    • Latin America
      • Brazil
      • Mexico
    • MEA
      • South Africa
      • Saudi Arabia

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38979

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Rat And Mouse Model Market, By Type

7.1.  Rat And Mouse Model Market, by Type, 2021-2030

7.1.1.    Knockout

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Knock-in

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Outbred

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Inbred

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Rat And Mouse Model Market, By Technology

8.1.  Rat And Mouse Model Market, by Technology, 2021-2030

8.1.1.    Nuclear transferase

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Microinjection

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Embryonic stem cells

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    CRISPR/Cas9

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Rat And Mouse Model Market, By Service

9.1.  Rat And Mouse Model Market, by Service, 2021-2030

9.1.1.    Cryopreservation

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Breeding

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Rederivation

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Genetic testing

9.1.4.1.        Market Revenue and Forecast (2017-2030)

9.1.5.    Quarantine depending

9.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Rat And Mouse Model Market, By Application

10.1.        Rat And Mouse Model Market, by Application, 2021-2030

10.1.1.  Cardiovascular diseases

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Genetic diseases

10.1.2.1.      Market Revenue and Forecast (2017-2030)

10.1.3.  Cancer

10.1.3.1.      Market Revenue and Forecast (2017-2030)

10.1.4.  Infectious diseases

10.1.4.1.      Market Revenue and Forecast (2017-2030)

10.1.5.  Transplantation

10.1.5.1.      Market Revenue and Forecast (2017-2030)

10.1.6.  Toxicology studies

10.1.6.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Rat And Mouse Model Market, By End-use

11.1.        Rat And Mouse Model Market, by End-use, 2021-2030

11.1.1.  Pharmaceutical companies

11.1.1.1.      Market Revenue and Forecast (2017-2030)

11.1.2.  Academic and research facilities

11.1.2.1.      Market Revenue and Forecast (2017-2030)

11.1.3.  Biotechnology companies

11.1.3.1.      Market Revenue and Forecast (2017-2030)

11.1.4.  Contract research & manufacturing organizations

11.1.4.1.      Market Revenue and Forecast (2017-2030)

Chapter 12.      Global Rat And Mouse Model  Market, Regional Estimates and Trend Forecast

12.1.        North America

12.1.1.  Market Revenue and Forecast, by Type (2017-2030)

12.1.2.  Market Revenue and Forecast, by Technology (2017-2030)

12.1.3.  Market Revenue and Forecast, by Service (2017-2030)

12.1.4.  Market Revenue and Forecast, by Application (2017-2030)

12.1.5.  Market Revenue and Forecast, by End-use (2017-2030)

12.1.6.  U.S.

12.1.6.1.      Market Revenue and Forecast, by Type (2017-2030)

12.1.6.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.1.6.3.      Market Revenue and Forecast, by Service (2017-2030)

12.1.6.4.      Market Revenue and Forecast, by Application (2017-2030)

12.1.6.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.1.7.  Rest of North America

12.1.7.1.      Market Revenue and Forecast, by Type (2017-2030)

12.1.7.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.1.7.3.      Market Revenue and Forecast, by Service (2017-2030)

12.1.7.4.      Market Revenue and Forecast, by Application (2017-2030)

12.1.7.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.2.        Europe

12.2.1.  Market Revenue and Forecast, by Type (2017-2030)

12.2.2.  Market Revenue and Forecast, by Technology (2017-2030)

12.2.3.  Market Revenue and Forecast, by Service (2017-2030)

12.2.4.  Market Revenue and Forecast, by Application (2017-2030)

12.2.5.  Market Revenue and Forecast, by End-use (2017-2030)

12.2.6.  UK

12.2.6.1.      Market Revenue and Forecast, by Type (2017-2030)

12.2.6.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.2.6.3.      Market Revenue and Forecast, by Service (2017-2030)

12.2.6.4.      Market Revenue and Forecast, by Application (2017-2030)

12.2.6.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.2.7.  Germany

12.2.7.1.      Market Revenue and Forecast, by Type (2017-2030)

12.2.7.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.2.7.3.      Market Revenue and Forecast, by Service (2017-2030)

12.2.7.4.      Market Revenue and Forecast, by Application (2017-2030)

12.2.7.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.2.8.  France

12.2.8.1.      Market Revenue and Forecast, by Type (2017-2030)

12.2.8.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.2.8.3.      Market Revenue and Forecast, by Service (2017-2030)

12.2.8.4.      Market Revenue and Forecast, by Application (2017-2030)

12.2.8.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.2.9.  Rest of Europe

12.2.9.1.      Market Revenue and Forecast, by Type (2017-2030)

12.2.9.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.2.9.3.      Market Revenue and Forecast, by Service (2017-2030)

12.2.9.4.      Market Revenue and Forecast, by Application (2017-2030)

12.2.9.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.3.        APAC

12.3.1.  Market Revenue and Forecast, by Type (2017-2030)

12.3.2.  Market Revenue and Forecast, by Technology (2017-2030)

12.3.3.  Market Revenue and Forecast, by Service (2017-2030)

12.3.4.  Market Revenue and Forecast, by Application (2017-2030)

12.3.5.  Market Revenue and Forecast, by End-use (2017-2030)

12.3.6.  India

12.3.6.1.      Market Revenue and Forecast, by Type (2017-2030)

12.3.6.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.3.6.3.      Market Revenue and Forecast, by Service (2017-2030)

12.3.6.4.      Market Revenue and Forecast, by Application (2017-2030)

12.3.6.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.3.7.  China

12.3.7.1.      Market Revenue and Forecast, by Type (2017-2030)

12.3.7.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.3.7.3.      Market Revenue and Forecast, by Service (2017-2030)

12.3.7.4.      Market Revenue and Forecast, by Application (2017-2030)

12.3.7.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.3.8.  Japan

12.3.8.1.      Market Revenue and Forecast, by Type (2017-2030)

12.3.8.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.3.8.3.      Market Revenue and Forecast, by Service (2017-2030)

12.3.8.4.      Market Revenue and Forecast, by Application (2017-2030)

12.3.8.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.3.9.  Rest of APAC

12.3.9.1.      Market Revenue and Forecast, by Type (2017-2030)

12.3.9.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.3.9.3.      Market Revenue and Forecast, by Service (2017-2030)

12.3.9.4.      Market Revenue and Forecast, by Application (2017-2030)

12.3.9.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.4.        MEA

12.4.1.  Market Revenue and Forecast, by Type (2017-2030)

12.4.2.  Market Revenue and Forecast, by Technology (2017-2030)

12.4.3.  Market Revenue and Forecast, by Service (2017-2030)

12.4.4.  Market Revenue and Forecast, by Application (2017-2030)

12.4.5.  Market Revenue and Forecast, by End-use (2017-2030)

12.4.6.  GCC

12.4.6.1.      Market Revenue and Forecast, by Type (2017-2030)

12.4.6.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.4.6.3.      Market Revenue and Forecast, by Service (2017-2030)

12.4.6.4.      Market Revenue and Forecast, by Application (2017-2030)

12.4.6.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.4.7.  North Africa

12.4.7.1.      Market Revenue and Forecast, by Type (2017-2030)

12.4.7.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.4.7.3.      Market Revenue and Forecast, by Service (2017-2030)

12.4.7.4.      Market Revenue and Forecast, by Application (2017-2030)

12.4.7.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.4.8.  South Africa

12.4.8.1.      Market Revenue and Forecast, by Type (2017-2030)

12.4.8.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.4.8.3.      Market Revenue and Forecast, by Service (2017-2030)

12.4.8.4.      Market Revenue and Forecast, by Application (2017-2030)

12.4.8.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.4.9.  Rest of MEA

12.4.9.1.      Market Revenue and Forecast, by Type (2017-2030)

12.4.9.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.4.9.3.      Market Revenue and Forecast, by Service (2017-2030)

12.4.9.4.      Market Revenue and Forecast, by Application (2017-2030)

12.4.9.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.5.        Latin America

12.5.1.  Market Revenue and Forecast, by Type (2017-2030)

12.5.2.  Market Revenue and Forecast, by Technology (2017-2030)

12.5.3.  Market Revenue and Forecast, by Service (2017-2030)

12.5.4.  Market Revenue and Forecast, by Application (2017-2030)

12.5.5.  Market Revenue and Forecast, by End-use (2017-2030)

12.5.6.  Brazil

12.5.6.1.      Market Revenue and Forecast, by Type (2017-2030)

12.5.6.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.5.6.3.      Market Revenue and Forecast, by Service (2017-2030)

12.5.6.4.      Market Revenue and Forecast, by Application (2017-2030)

12.5.6.5.      Market Revenue and Forecast, by End-use (2017-2030)

12.5.7.  Rest of LATAM

12.5.7.1.      Market Revenue and Forecast, by Type (2017-2030)

12.5.7.2.      Market Revenue and Forecast, by Technology (2017-2030)

12.5.7.3.      Market Revenue and Forecast, by Service (2017-2030)

12.5.7.4.      Market Revenue and Forecast, by Application (2017-2030)

12.5.7.5.      Market Revenue and Forecast, by End-use (2017-2030)

Chapter 13.  Company Profiles

13.1.              Charles River Laboratories International, Inc.

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.              The Jackson Laboratory

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.              Laboratory Corporation of America Holdings (Covance)

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.              Perkin Elmer (Horizon Discovery Group plc)

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.              genOway

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.              Envigo

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.              JANVIER LABS

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.              Taconic Biosciences, Inc.

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.              Biomedical Research Models (Biomere)

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.           Transpogen Biopharmaceutical, Inc.

13.10.1.               Company Overview

13.10.2.               Product Offerings

13.10.3.               Financial Performance

13.10.4.               Recent Initiatives

Chapter 14.  Research Methodology

14.1.              Primary Research

14.2.              Secondary Research

14.3.              Assumptions

Chapter 15.  Appendix

15.1.              About Us

15.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38979

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com